Seems like a few healthcare stocks going on a move of late and...

Seems like a few healthcare stocks going on a move of late and the market finally waking up to how undervalued PIQ is compared to peers.

RHY - mkt cap ~$140m, large potential market but still a few years away (1-2 years?) from test hitting the mkt, no pipeline mentioned in AGM Preso.

RENX/RNLX - mkt cap ~A$700m, smaller target market than PIQ (going after late stage DKD), no commercial sales, no CE Mark, no pipeline mentioned in company presos.

PIQ - mkt cap $58m - large target market, test is CE Mark approved, initial licence deals executed, first sales in in CY21, broad/deep pipeline of other diagnostic tests.

Plus other mkt caps in peer group table below:

If PIQ has a market cap of $140m, like RHY, share price will be $1.33

If PIQ has a market cap of the ave of some of its peers below, say $250m, share price will be $2.38

I'll leave everyone to do their own calcs for what the SP would be if they get to RENX's mkt cap....



------------------------------------------------------------

This is a quoted post from@Tulip2000

This is spot on, this was before the announcement of an FDA application. IMO it's not unreasonable for a fair valuation of $250-300M ($2.5-$3) market cap right now. And if the FDA approval comes through, this is a willy wonka golden ticket and should come with a re-rating, it's not unreasonable to expect a $500-600M market cap, or about $6-7 per share. Then, it would be a matter of the up take and commercial rollout/update, in which there is infinite upside. And this is just for PromarkerD. We still have so much other R & D in the pipeline. My favorite is the endo test. A endometriosis test would be a game changer, currently there is no known test other than invasive surgery. All IMO. GLTAH.